To own Viking Therapeutics, you need to believe VK2735 can move from promising obesity data to a real commercial franchise while the group is still loss making and pre revenue. The recent VENTURE analysis supports a multi risk factor obesity story that speaks directly to long term treatment use rather than short cosmetic weight loss alone.
In the near term, the key catalyst remains clean, convincing outcomes from the long duration VANQUISH trials that underpin any future approval path. The largest risk is still binary trial and safety execution, magnified by heavy R&D spend, no current revenue, and reliance on cash reserves and potential future equity funding.
The ObesityWeek poster on the VANQUISH 2 baseline population looks dry at first glance but matters for you as a shareholder. Management is signaling that this Phase 3 cohort closely matches adults in the U.S. with BMI of at least 27 and type 2 diabetes, which helps frame how regulators and payers may view the data set.
That context ties straight into catalysts and risk. VANQUISH 2 is designed around 78 week weight loss and broader safety outcomes, and the analyst consensus Narrative on Simply Wall St points to VK2735 as Viking Therapeutics' central commercial opportunity. Any issues recruiting, retaining, or treating this real world style population would cut directly against that thesis.
Viking Therapeutics' narrative projects US$118.5 million revenue and US$12.9 million earnings by 2029. This implies revenue rising from zero and an earnings increase of about US$372.5 million from current earnings of a US$359.6 million loss.
Uncover why Viking Therapeutics' fair value indicates a 245% potential upside to its current price that could narrow quickly.
One alternate, very bullish view treats the new VK2735 obesity data as a possible accelerant to an already aggressive revenue story for Viking Therapeutics. Before this ObesityWeek update, the most optimistic analysts were pencilling in about US$1.3b of sales and US$214.5 million of earnings by 2029. That is a far brighter picture than the consensus, and it shows how far opinions can stretch. Use this spread in expectations as a cue to explore multiple narratives rather than anchor only on one set of forecasts that may shift as fresh data land.
Explore 3 other Viking Therapeutics fair value estimates, including one that suggests as much as 255% potential upside from the current price.
Disagree with existing narratives? Extraordinary investment results rarely come from following the herd, so consider trusting your own analysis.
If the Viking Therapeutics story has sharpened your thinking and you want to apply that lens more broadly, the Simply Wall St Screener can help you turn loose ideas into a focused watchlist.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com